Caris Assure Blood Based Profiling


Less Invasive, More Intelligent Than Ever

Caris-Assure-Vertical-White-2

Be Sure with Caris Assure

With deep molecular insights from a simple blood sample, Caris Assure™ offers a minimally-invasive liquid biopsy option for biomarker analysis of cancer patients when tissue samples are not available. No matter the specimen type – tissue or blood – Caris Life Sciences’ flexible, multi-faceted molecular profiling platforms deliver uncompromising reliability and performance to guide personalized treatment decisions and help improve patient outcomes.*

The Most Powerful Liquid Biopsy Assay Ever Developed.


Technology
Circulating Nucleic Acid Sequencing
(cNAS)


Application
Biomarker Analysis (including resistance mutations)


Biological Coverage
Plasma: cfDNA, cfRNA
White Blood Cells: gDNA, mRNA


Variant Coverage (pathogenic and likely pathogenic)
Tumor-Derived   Incidental Germline†    Incidental CHIP


Genes & Depth
23,000+  8,000x (raw average for clinically relevant genes)


Next Generation Sequencing
Whole Exome
Whole Transcriptome


Alterations
SNV  INDEL  CNA  Fusions


Genomic Signatures/Other
bTMB  HLA Genotype  MSI


Sample Quantity
Two Tubes Whole Blood


Performance in Advanced/Metastatic Patients
Compared to matched tissue collected within 30 days; based on ≥5 ng of cNAS input.
Clinically Actionable SNV and INDEL:
Sensitivity 93.8%
Specificity >99.9%
PPV 96.8%
LOD 0.1% VAF
Incidental Germline :
Sensitivity >99%
Specificity >99%
PPV >99%

Whole Exome and Whole Transcriptome Sequencing from Blood

Caris Assure analyzes 23,000+ genes using whole exome and whole transcriptome sequencing, providing the most robust and accurate assessment of the key molecular features of a patient’s cancer. This comprehensive approach identifies all pan-cancer biomarkers, including a wide range of variant types and genomic signatures. 

Tumor-Derived, Incidental Germline and Incidental CHIP Detection in a Single Assay

Caris Assure analyzes both plasma and buffy coat (white blood cell) layers, distinguishing tumor-derived somatic variants from incidental germline or incidental CHIP variants. The Caris Assure report subtracts incidental CHIP mutations from somatic tumor mutations to reduce false positives and improve assay reliability.

Looking for a Specific Gene?

Use our full gene search to verify that it is included in Caris profiling, or browse the list of genes most commonly associated with cancer.

Search Genes >

Liquid Profiling Blood Plasma Buffy Coat Testing Image

Sign Up to Learn More

Sign up to receive updates about Caris Assure features and availability.

The online form below is intended for healthcare professionals only. If you are a patient, please contact your doctor for more information about Caris Assure. Not available in all locations.

Name(Required)
This field is for validation purposes and should be left unchanged.

* Caris Assure is intended for patients with previously diagnosed solid malignant neoplasms where tissue is not available, and is to be used by qualified healthcare professionals. Not available in all locations.

† Not a replacement for comprehensive germline testing. Incidental pathogenic alterations detected in ACMG recognized cancer genes are reported. Negative results do not imply the patient does not harbor a germline mutation.

Order Profiling

Place an order today for a comprehensive, personalized Caris profiling report.